Efficacy and safety of azathioprine during remission of immune-mediated thrombotic thrombocytopenic purpura.
作者信息
Bichard Christian, Mancini Ilaria, Agosti Pasquale, Capecchi Marco, De Leo Pasqualina, Arcudi Sara, Ferrari Barbara, Trisolini Silvia Maria, Longu Francesco, Fozza Claudio, Artoni Andrea, Peyvandi Flora
机构信息
Università degli Studi di Milano, Milan, Italy.
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy and Fondazione Luigi Villa, Milan, Italy.
出版信息
Blood Adv. 2022 Sep 27;6(18):5463-5466. doi: 10.1182/bloodadvances.2022007632.
Abstract
摘要
相似文献
1
Efficacy and safety of azathioprine during remission of immune-mediated thrombotic thrombocytopenic purpura.硫唑嘌呤在免疫介导的血栓性血小板减少性紫癜缓解期的疗效及安全性
Blood Adv. 2022 Sep 27;6(18):5463-5466. doi: 10.1182/bloodadvances.2022007632.
2
Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura.硼替佐米可诱导复发难治性特发性血栓性血小板减少性紫癜患者临床缓解并降低ADAMTS13抑制性抗体水平。
Br J Haematol. 2014 Mar;164(6):900-2. doi: 10.1111/bjh.12696. Epub 2013 Dec 17.
3
Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.获得性血栓性血小板减少性紫癜患者循环中ADAMTS13特异性免疫复合物的持续存在。
Haematologica. 2014 Apr;99(4):779-87. doi: 10.3324/haematol.2013.094151. Epub 2013 Nov 15.
4
ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.ADAMTS13和抗ADAMTS13抗体作为获得性血栓性血小板减少性紫癜缓解期复发的标志物。
Haematologica. 2008 Feb;93(2):232-9. doi: 10.3324/haematol.11739. Epub 2008 Jan 26.
5
Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura. Reply.重组ADAMTS13用于免疫性血栓性血小板减少性紫癜。回复。
N Engl J Med. 2024 Jul 25;391(4):383-384. doi: 10.1056/NEJMc2406975.
6
A case of severe ADAMTS13 deficiency presenting as thrombotic thrombocytopenic purpura in pregnancy.一例以妊娠期血栓性血小板减少性紫癜为表现的严重ADAMTS13缺乏症病例。
Med Pregl. 2012 Sep-Oct;65(9-10):436-9. doi: 10.2298/mpns1210436n.
7
Rituximab for thrombotic thrombocytopenic purpura.
Isr Med Assoc J. 2011 Jul;13(7):436-7.
8
Current management of thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜的当前管理
Curr Opin Hematol. 2008 Sep;15(5):445-50. doi: 10.1097/MOH.0b013e328309ec62.
9
Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura.预防性环孢素治疗对特发性血栓性血小板减少性紫癜患者ADAMTS13生物标志物的影响。
Am J Hematol. 2008 Dec;83(12):911-5. doi: 10.1002/ajh.21281.
10
Congenital ADAMTS13 deficiency: a rare mimicker of immune thrombocytopenic purpura.先天性ADAMTS13缺乏症：一种罕见的免疫性血小板减少性紫癜模仿者。
J Pediatr Hematol Oncol. 2014 Nov;36(8):653-5. doi: 10.1097/MPH.0000000000000180.
引用本文的文献
1
How we manage immune-mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance.利妥昔单抗治疗失败或不耐受后，我们如何管理免疫介导的血栓性血小板减少性紫癜。
Br J Haematol. 2025 Jun;206(6):1560-1570. doi: 10.1111/bjh.20101. Epub 2025 Apr 24.
2
A Systematic Review of the Epidemiology and Disease Burden of Congenital and Immune-Mediated Thrombotic Thrombocytopenic Purpura.先天性和免疫介导性血栓性血小板减少性紫癜的流行病学及疾病负担的系统评价
J Blood Med. 2024 Aug 14;15:363-386. doi: 10.2147/JBM.S464365. eCollection 2024.
本文引用的文献
1
Redefining outcomes in immune TTP: an international working group consensus report.重新定义免疫性血栓性血小板减少性紫癜的结局：国际工作组共识报告。
Blood. 2021 Apr 8;137(14):1855-1861. doi: 10.1182/blood.2020009150.
2
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.国际血栓与止血学会（ISTH）血栓性血小板减少性紫癜治疗指南。
J Thromb Haemost. 2020 Oct;18(10):2496-2502. doi: 10.1111/jth.15010. Epub 2020 Sep 11.
3
Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study.德国获得性血栓性血小板减少性紫癜的发病率：一项医院层面的研究。
Orphanet J Rare Dis. 2019 Nov 15;14(1):260. doi: 10.1186/s13023-019-1240-0.
4
Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopenic Purpura: Fourteen Years of the Milan TTP Registry.获得性血栓性血小板减少性紫癜患者的临床和实验室特征：米兰 TTP 登记处 14 年的经验。
Thromb Haemost. 2019 May;119(5):695-704. doi: 10.1055/s-0039-1679907. Epub 2019 Mar 12.
5
Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine.血栓性血小板减少性紫癜：迈向靶向治疗与精准医学
Res Pract Thromb Haemost. 2018 Nov 16;3(1):26-37. doi: 10.1002/rth2.12160. eCollection 2019 Jan.
6
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.预防性利妥昔单抗可预防免疫介导性血栓性血小板减少性紫癜的长期复发。
Blood. 2018 Nov 15;132(20):2143-2153. doi: 10.1182/blood-2018-04-840090. Epub 2018 Sep 10.
7
Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura.临床因素和生物标志物可预测免疫性血栓性血小板减少性紫癜患者的结局。
Haematologica. 2019 Jan;104(1):166-175. doi: 10.3324/haematol.2018.198275. Epub 2018 Aug 31.
8
Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens.利妥昔单抗预防血栓性血小板减少性紫癜复发：治疗结果及给药方案评估
Blood Adv. 2017 Jun 26;1(15):1159-1166. doi: 10.1182/bloodadvances.2017008268. eCollection 2017 Jun 27.
9
Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.血栓性血小板减少性紫癜：1995年至2015年的诊断标准、临床特征及长期预后
Blood Adv. 2017 Apr 6;1(10):590-600. doi: 10.1182/bloodadvances.2017005124. eCollection 2017 Apr 11.
10
Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.血栓性血小板减少性紫癜及相关血栓性微血管病术语标准化的共识。
J Thromb Haemost. 2017 Feb;15(2):312-322. doi: 10.1111/jth.13571. Epub 2017 Jan 30.
Zotero 插件